ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

3:00PM-4:30PM
Abstract Number: 2614
Risk of New Onset of Immune-Mediated Diseases After Sars-Cov-2 Infection: A Systematic Review and Meta-Analysis
Abstracts: Infection-related Rheumatic Disease
3:00PM-4:30PM
Abstract Number: 2619
Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients
Abstracts: Measures & Measurement of Healthcare Quality
3:00PM-4:30PM
Abstract Number: 2656
Short-Term Effectiveness of a Walk with Ease Program Delivered by Telephone on Arthritis-Related Symptoms, Function, and Physical Activity
Abstracts: ARP Interprofessional II: Psychology & Practice
3:00PM-4:30PM
Abstract Number: 2595
TGF-β Activated Kinase 1 (TAK1) Inhibition Suppresses Synovial Inflammation and Tissue Destruction Mediated by Activated Juvenile Idiopathic Arthritis Synovial Fibroblasts
Abstracts: Cytokines & Cell Trafficking
3:00PM-4:30PM
Abstract Number: 2597
The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
Abstracts: Cytokines & Cell Trafficking
3:00PM-4:30PM
Abstract Number: 2634
Transcriptomic Stratification Predicts Response to Rituximab, Abatacept or the Association of Hydroxychloroquine and Leflunomide in 3 Randomized Controlled Clinical Trials in Sjögren’s Disease
Abstracts: Sjögren's Syndrome – Basic & Clinical Science
3:00PM-4:30PM
Abstract Number: 2610
Treatment Concordance of Asynchronous Virtual Visits Compared to Traditional In-person Visits in Patients with Rheumatoid Arthritis: Results of the Prospective, Multi-center, Randomized Controlled TELERA Trial
Abstracts: Health Services Research II
3:00PM-4:30PM
Abstract Number: 2621
Trends in Disease Activity in Rheumatoid Arthritis over 2009-2023 Utilizing DAS28-CRP Inferred from Electronic Health Records
Abstracts: Measures & Measurement of Healthcare Quality
3:00PM-4:30PM
Abstract Number: 2612
Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients Vaccinated with Recombinant Herpes Zoster Vaccine: An Interim Analysis of a Prospective Randomized Phase 4 Study
Abstracts: Infection-related Rheumatic Disease
3:00PM-4:30PM
Abstract Number: 2613
Vaccination Is Associated with Lower Risk of Parenchymal Lung Disease in Patients with Rheumatoid Arthritis After COVID-19: Results from a Prospective Study
Abstracts: Infection-related Rheumatic Disease
3:00PM-4:30PM
Abstract Number: 2651
Vasculitis Associated with VEXAS Syndrome
Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II
3:00PM-4:30PM
Abstract Number: 2599
Xist Deletion in B Cells Results in Systemic Lupus Erythematosus Phenotypes
Abstracts: SLE – Etiology & Pathogenesis
  • «Previous Page
  • 1
  • …
  • 59
  • 60
  • 61
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology